Evaluation of the therapeutic effect of treatment with intra-articular hyaluronic acid in knees for Kashin-Beck disease: A meta-analysis

Yu, Fangfang; Xia, Chuantao; Hua, Fang; Han, Jing; Younus, Mohammad; Guo, Xiong

doi:10.1016/j.joca.2014.04.012

Cited by 17 publications

(13 citation statements)

References 21 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, the increasing recognition of environmental risk factors for the development of clinical KBD and the advent of highly sensitive imaging modalities for visualizing cartilage damage, as well as early synovitis may greatly enhance the appreciation of early anti-inflammatory interventions. Current therapies, such as selenium, intra-articular hyaluronic acid injections, nonsteroidal anti-inflammatory drugs (NSAID), COX-2 selective agents, vitamins and chondroitin sulfate showed efficiency for relieving discomfort of KBD patients [11][12][13][14][15][16][17][18]. Although several studies have demonstrated that the efficacy of meloxicam [13,49], a COX-2-specific inhibitor, is effective in the treatment of knee pain due to KBD, no agent has been shown to have disease modifying effects on the structural progression of KBD.…”

Section: Inflammation As a Target For Treatment Of Kbdmentioning

confidence: 99%

See 1 more Smart Citation

Role of inflammation in the process of clinical Kashin-Beck disease: latest findings and interpretations

Han

Wang

et al. 2015

Inflamm. Res.

View full text Add to dashboard Cite

Kashin-Beck disease (KBD), a particular type of osteoarthritis (OA), and an endemic disease with articular cartilage damage and chondrocytes apoptosis, can affect many joints, and the most commonly affected joints are the knee, ankle, and hand. KBD has traditionally been classified as a non-inflammatory OA. However, recent studies have shown that inflammation has played an important role in the development of KBD. Nowadays, clinical KBD is not only an endemic disease, but also a combined result of many other non-endemic factors, which contains age, altered biomechanics, joint trauma and secondary OA. The characteristics of the developmental joint failure of advanced KBD, because of the biochemical and mechanical processes, are tightly linked with the interaction of joint damage and its immune response, as well as the subsequent state of chronic inflammation leading to KBD progression. In this review, we focus on the epidemiology, pathology, imaging, cytokines and transduction pathways investigating the association of inflammation with KBD; meanwhile, a wide range of data will be discussed to elicit our current hypotheses considering the role of inflammation and immune activation in KBD development.

show abstract

Section: Inflammation As a Target For Treatment Of Kbdmentioning

confidence: 99%

“…For the prevention or treatment of KBD, sodium selenite [11,12], pain killers and anti-inflammatory drugs [13], vitamins [14], hyaluronic acid [15], chondroitin sulfate and glucosamine [16] have been used. Thanks to these measures, KBD in children is under control and has almost disappeared today.…”

Section: Introductionmentioning

confidence: 99%

Role of inflammation in the process of clinical Kashin-Beck disease: latest findings and interpretations

Han

Wang

et al. 2015

Inflamm. Res.

View full text Add to dashboard Cite

show abstract

“…[20,21]. Studies focusing on treatment evaluation have shown that medication, physical therapy, and surgery can help to alleviate symptoms, delay cartilage degeneration, and improve joint function [6][7][8][9][10][11][12]. In addition, results from 2520 children and adults with KBD (ages, 1-60 years) using single-factor logistic regression modeling showed that, along with increased age and prolonged disease, the major indicators of KBD were joint pain, morning stiffness, joint dysfunction (wrist, elbow, ankle, knee, and shoulder), finger coarse, bone end, knee deformity, and scoliosis [22].…”

Section: Feasibility Analysismentioning

confidence: 99%

“…The WOMAC score was employed to compare the efficacy of celecoxib, meloxicam, and paracetamol in elderly subjects with KBD [11]. Collectively, the Lysholm score, WOMAC score, Lequence score, VAS score, HSS score, functional score, and SF-12 represent different application of the osteoarthritis scale [12].…”

Section: Introductionmentioning

confidence: 99%

Reliability and validation of the joint dysfunction index as a new assessment instrument for therapeutic efficacy for Kashin-Beck disease

Xia

Hua

et al. 2016

Clin Rheumatol

View full text Add to dashboard Cite

The objective of this study was to evaluate the reliability and validity of the joint dysfunction index (JDI) for assessment of therapeutic efficacy for Kashin-Beck disease (KBD). In an initial survey, completed questionnaires were obtained from 276 of 281 patients (98.2 %). A follow-up survey was completed with 64 KBD patients among 276 cases. A third survey selected 60 KBD patients who underwent intra-articular injection of sodium hyaluronate in the knees ascertained from the findings of the second questionnaire. Reliability was assessed using test-retest, "split-half" reliability and Cronbach's alpha coefficient. Factor analysis and item-to-domain correlation were used to analyze validity. The coefficient of variation (CV) was used to measure the sensitivity of scale. Feasibility assessment included consideration of completion time, rate of recovery, and time of completion. Reliability analysis comprised a test-retest correlation coefficient of 0.404-0.546 and a kappa test of 0.404-0.546. Internal consistency analysis comprised a Cronbach alpha coefficient of 0.689 and a split-half coefficient of 0.677. Principal component factor analysis for validity testing extracted a common factor with a cumulative variance contribution of 45.44 %. The JDI score from 276 KBD cases revealed no significant difference associated with age, gender, education, or the body mass index. Sensitivity analysis showed that there was no significant difference between pre-treatment and post-treatment values, with a CV of 96.55-172.06 %. In conclusion, the JDI can be used to evaluate the efficacy of agents used to treat KBD.

show abstract

“…Both HA and HA binding protein (HABP) are important components of articular cartilage whose damage is the principal pathologic feature of KBD [18]. Intra-articular hyaluronic acid (IAHA) injection has been used to treat patients with KBD [19]. Therefore, we also investigated the potential association between KBD susceptibility and variants in COL10A1 and HABP2 genes by directly sequencing the exons of both genes.…”

Section: Introductionmentioning

confidence: 99%

Association study of candidate genes for susceptibility to Kashin-Beck disease in a Tibetan population

et al. 2017

View full text Add to dashboard Cite

BackgroundMany osteoarthritis (OA) susceptibility genes have been identified in recent years. Given the overlap in the phenotype of joint inflammation between OA and Kashin-Beck disease (KBD), the aim of this study is to explore whether the reported OA susceptibility genes and two genes that may link to OA pathophysiology are associated with KBD in the Tibetan population.MethodFifteen single-nucleotide polymorphisms (SNPs) in 12 candidate genes previously reported as OA susceptibility loci were selected for investigation. Genotyping was performed using the SNaPshot method for these SNPs in a Tibetan population composed of 849 KBD patients and 565 normal controls. Meanwhile, the coding regions of two genes, COL10A1 and HABP2, which may involve in the pathological mechanism of OA/KBD, were sequenced by Sanger sequencing to identify susceptibility coding variants for KBD in the Tibetan population.ResultsThe two arthritis-susceptible candidate SNPs, rs7775 (p.Arg324Gly) in the FRZB gene and rs7033979 in the ASPN gene, showed associations with KBD (OR = 1.568, P = 4 × 10−3 and OR = 0.744, P = 8 × 10−3, respectively). The coding variants rs142463796 (p.Asp128Asn) and rs2228547 (p.Gly545Arg) in the COL10A1 gene (OR = 9.832 and P = 6 × 10−3 and OR = 1.242, P = 0.043, respectively) and rs548354451 (p.Asp272Glu) in the HABP2 gene (OR = 2.813, P = 0.010) were associated with KBD patients.ConclusionThese finding suggested that rs7775 in the FRZB gene may increase susceptibility to KBD, while rs7033979 in the ASPN gene may play a protective role in susceptibility to KBD in Tibetans. Moreover, genetic variants in chondrogenesis-related genes COL10A1 and HABP2 may play a role in the risk of developing KBD in the Tibetan population.Electronic supplementary materialThe online version of this article (doi:10.1186/s12881-017-0423-6) contains supplementary material, which is available to authorized users.

show abstract

Evaluation of the therapeutic effect of treatment with intra-articular hyaluronic acid in knees for Kashin-Beck disease: A meta-analysis

Abstract: IAHA for the treatment of KBD was safe and efficacious at 12 months with low and transient adverse reactions. However, more high-quality randomized controlled trials (RCTs) are needed to confirm its therapeutic effect.

Cited by 17 publications

References 21 publications

Role of inflammation in the process of clinical Kashin-Beck disease: latest findings and interpretations

Role of inflammation in the process of clinical Kashin-Beck disease: latest findings and interpretations

Reliability and validation of the joint dysfunction index as a new assessment instrument for therapeutic efficacy for Kashin-Beck disease

Association study of candidate genes for susceptibility to Kashin-Beck disease in a Tibetan population

Contact Info

Product

Resources

About